1. Home
  2. AEC vs MDWD Comparison

AEC vs MDWD Comparison

Compare AEC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEC

Anfield Energy Inc.

N/A

Current Price

$5.35

Market Cap

165.3M

Sector

Real Estate

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.70

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEC
MDWD
Founded
1989
2000
Country
Canada
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
193.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AEC
MDWD
Price
$5.35
$16.70
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
40.1K
102.9K
Earning Date
05-01-2015
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
N/A
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.42
$14.90
52 Week High
$12.49
$22.51

Technical Indicators

Market Signals
Indicator
AEC
MDWD
Relative Strength Index (RSI) 45.75 45.04
Support Level $5.50 $14.90
Resistance Level $6.04 $18.62
Average True Range (ATR) 0.46 0.83
MACD 0.07 0.03
Stochastic Oscillator 37.27 41.22

Price Performance

Historical Comparison
AEC
MDWD

About AEC Anfield Energy Inc.

Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One. The company's geographical segments are Canada and the United States.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: